# Trade Mark Journal No.2026/013 27 March 2026

## WO0000001906873 (40,42)

Office of origin: United States of America

Date of International Registration:26 January 2026
Date of designation in the UK: 26 January 2026

International priority date claimed: 18 December 2025 (United States of America) (99555535)

Class 40
  Providing technical information in the field of pharmaceutical manufacturing; manufacturing services for others in the field of sirna synthesis; custom manufacture of sirna therapeutics; custom manufacture of rna utilizing proprietary enzymatic technologies to enable nucleic acid therapeutics development.
Class 42
  Scientific research and development; research and development of small molecule RNA drugs; research and development of siRNA drugs; RNA interference technology research.

Alnylam Pharmaceuticals, Inc.

Representative: Sarah Anne Keefe Womble Bond Dickinson (US) LLP, 470 Atlantic Avenue, Suite 600, Boston MA 02210, UNITED STATES OF AMERICA